JP2017501200A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017501200A5 JP2017501200A5 JP2016544111A JP2016544111A JP2017501200A5 JP 2017501200 A5 JP2017501200 A5 JP 2017501200A5 JP 2016544111 A JP2016544111 A JP 2016544111A JP 2016544111 A JP2016544111 A JP 2016544111A JP 2017501200 A5 JP2017501200 A5 JP 2017501200A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutically acceptable
- pharmaceutical composition
- disease
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims 16
- 201000011510 cancer Diseases 0.000 claims 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 16
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 150000001875 compounds Chemical class 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 8
- 208000035475 disorder Diseases 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 7
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 7
- 239000002955 immunomodulating agent Substances 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 6
- 229940000425 combination drug Drugs 0.000 claims 5
- 230000000694 effects Effects 0.000 claims 4
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 3
- 206010060862 Prostate cancer Diseases 0.000 claims 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 3
- 201000005202 lung cancer Diseases 0.000 claims 3
- 208000020816 lung neoplasm Diseases 0.000 claims 3
- 230000001419 dependent effect Effects 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical group N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 1
- 102000009618 Transforming Growth Factors Human genes 0.000 claims 1
- 108010009583 Transforming Growth Factors Proteins 0.000 claims 1
- 238000009175 antibody therapy Methods 0.000 claims 1
- 238000002619 cancer immunotherapy Methods 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- -1 3-dihydroindolinyl Chemical group 0.000 description 15
- 125000000623 heterocyclic group Chemical group 0.000 description 8
- 125000001072 heteroaryl group Chemical group 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 5
- 125000002619 bicyclic group Chemical group 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- 125000005842 heteroatom Chemical group 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 125000006413 ring segment Chemical group 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 1
- 125000001698 2H-pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- BWESROVQGZSBRX-UHFFFAOYSA-N pyrido[3,2-d]pyrimidine Chemical compound C1=NC=NC2=CC=CN=C21 BWESROVQGZSBRX-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000005247 tetrazinyl group Chemical group N1=NN=NC(=C1)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000004525 thiadiazinyl group Chemical group S1NN=C(C=C1)* 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000005307 thiatriazolyl group Chemical group S1N=NN=C1* 0.000 description 1
- 125000004305 thiazinyl group Chemical group S1NC(=CC=C1)* 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN6/DEL/2014 | 2014-01-01 | ||
| IN6DE2014 | 2014-01-01 | ||
| PCT/US2014/072922 WO2015103355A1 (en) | 2014-01-01 | 2014-12-31 | Compounds and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019000208A Division JP2019048899A (ja) | 2014-01-01 | 2019-01-04 | 化合物及び使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017501200A JP2017501200A (ja) | 2017-01-12 |
| JP2017501200A5 true JP2017501200A5 (https=) | 2019-02-14 |
| JP6474166B2 JP6474166B2 (ja) | 2019-02-27 |
Family
ID=52293317
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016544111A Expired - Fee Related JP6474166B2 (ja) | 2014-01-01 | 2014-12-31 | 化合物及び使用方法 |
| JP2019000208A Pending JP2019048899A (ja) | 2014-01-01 | 2019-01-04 | 化合物及び使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019000208A Pending JP2019048899A (ja) | 2014-01-01 | 2019-01-04 | 化合物及び使用方法 |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US10030004B2 (https=) |
| EP (1) | EP3089971B1 (https=) |
| JP (2) | JP6474166B2 (https=) |
| CN (2) | CN106132950B (https=) |
| AU (2) | AU2014373773C1 (https=) |
| CA (1) | CA2935392C (https=) |
| CY (1) | CY1123290T1 (https=) |
| DK (1) | DK3089971T3 (https=) |
| ES (1) | ES2813875T3 (https=) |
| HR (1) | HRP20201384T1 (https=) |
| HU (1) | HUE050761T2 (https=) |
| LT (1) | LT3089971T (https=) |
| PL (1) | PL3089971T3 (https=) |
| PT (1) | PT3089971T (https=) |
| RS (1) | RS60718B1 (https=) |
| SI (1) | SI3089971T1 (https=) |
| WO (1) | WO2015103355A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20201384T1 (hr) | 2014-01-01 | 2020-11-27 | Medivation Technologies Llc | Spojevi i postupci njihove upotrebe |
| JP6952747B2 (ja) * | 2018-09-18 | 2021-10-20 | ファイザー・インク | がん処置のためのＴＧＦβ阻害剤およびＣＤＫ阻害剤の組合せ |
| JP7541924B2 (ja) | 2018-10-31 | 2024-08-29 | 千寿製薬株式会社 | 網膜神経節細胞死抑制剤 |
| MA54526A (fr) * | 2018-12-20 | 2022-03-30 | Pfizer | NOUVELLES FORMES POLYMORPHES D'UN INHIBITEUR DE TGFBeta |
| CA3117838A1 (en) * | 2018-12-27 | 2020-07-02 | Nexys Therapeutics, Inc. | (pyridin-2-yl)amine derivatives as tgf-beta r1 (alk5) inhibitors for the treatment of cancer |
| US12478624B2 (en) | 2019-10-02 | 2025-11-25 | Tolremo Therapeutics Ag | Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer |
| CN111116565B (zh) * | 2020-04-01 | 2020-07-14 | 中科利健制药(广州)有限公司 | 2-芳基-4-（4-吡唑氧基）吡啶类化合物、其制备方法、药物组合物与应用 |
| CA3184062A1 (en) * | 2020-06-25 | 2021-12-30 | Stefanie Fluckiger-Mangual | Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of fibrotic disease |
| IL299344A (en) | 2020-06-25 | 2023-02-01 | Tolremo Therapeutics Ag | Combination of a cbp/p300 bromodomain inhibitor and a kras inhibitor for the treatment of cancer |
| PT4182308T (pt) * | 2020-07-15 | 2024-12-04 | Chiesi Farm Spa | Derivados de piridazinil amino como inibidores de alk5 |
| CN114369083B (zh) * | 2020-10-15 | 2026-02-27 | 四川科伦博泰生物医药股份有限公司 | 杂环类化合物、包含其的药物组合物、其制备方法及其用途 |
| AU2021387908A1 (en) * | 2020-11-24 | 2023-06-22 | Aligos Therapeutics, Inc. | Tricyclic compounds |
| WO2022130206A1 (en) | 2020-12-16 | 2022-06-23 | Pfizer Inc. | TGFβr1 INHIBITOR COMBINATION THERAPIES |
| CN112843058A (zh) * | 2021-01-27 | 2021-05-28 | 复旦大学附属华山医院 | 烟酰胺类化合物在制备治疗抗脊索肿瘤药物中的应用 |
| BR112023020538A2 (pt) | 2021-04-07 | 2024-01-23 | Tolremo Therapeutics Ag | Derivados heterocíclicos, composições farmacêuticas e seus usos no tratamento ou na melhoria de câncer |
| WO2022229846A1 (en) | 2021-04-29 | 2022-11-03 | Pfizer Inc. | Treatment of cancer using a transforming growth factor beta receptor type 1 inhibitor |
| US20250034212A1 (en) | 2021-09-30 | 2025-01-30 | Peptidream Inc. | Peptide |
| CN115353326A (zh) * | 2022-07-27 | 2022-11-18 | 魏玉芝 | 一种反光防车印沥青及其制备方法 |
| CN116606244A (zh) * | 2023-05-26 | 2023-08-18 | 康化（上海）新药研发有限公司 | 一种6-溴-5-甲氧基吡啶-3-胺的合成方法 |
| CN117865965B (zh) * | 2024-01-08 | 2024-06-28 | 贵州省天然产物研究中心 | 吡咯并嘧啶-4-胺和吡唑并嘧啶-4-胺衍生物及制备方法和应用 |
Family Cites Families (98)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5714493A (en) | 1991-05-10 | 1998-02-03 | Rhone-Poulenc Rorer Pharmaceuticals, Inc. | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase |
| US5710158A (en) | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| US6645969B1 (en) | 1991-05-10 | 2003-11-11 | Aventis Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase |
| EP0640599B1 (en) | 1993-08-26 | 1998-03-04 | Ono Pharmaceutical Co., Ltd. | 4-Aminopyrimidine derivatives |
| US6184226B1 (en) | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
| WO2000047102A2 (en) | 1999-02-11 | 2000-08-17 | The General Hospital Corporation | COMPOSITIONS AND METHODS FOR MODULATING TGF-β SIGNALING |
| GB9922171D0 (en) | 1999-09-21 | 1999-11-17 | Zeneca Ltd | Chemical compounds |
| US6660731B2 (en) | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| EP1317450B1 (en) | 2000-09-15 | 2006-11-22 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US6613776B2 (en) | 2000-09-15 | 2003-09-02 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| NZ526472A (en) | 2000-12-21 | 2004-04-30 | Vertex Pharma | Pyrazole compounds useful as protein kinase inhibitors |
| AU2002352868A1 (en) | 2001-11-27 | 2003-06-10 | Merck & Co., Inc. | 4-aminoquinoline compounds |
| US20040006030A1 (en) | 2002-07-02 | 2004-01-08 | Isis Pharmaceuticals Inc. | Antisense modulation of TGF-beta 2 expression |
| US20030225089A1 (en) | 2002-04-10 | 2003-12-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors |
| EP1511738A4 (en) | 2002-05-17 | 2007-05-09 | Scios Inc | TREATMENT OF FIBROPROLIFERATIVE DISEASES USING TGF BETA INHIBITORS |
| US20040146509A1 (en) | 2002-07-25 | 2004-07-29 | Zhihe Li | Methods for improvement of lung function using TGF-beta inhibitors |
| JP2006503043A (ja) | 2002-09-10 | 2006-01-26 | サイオス インク． | ＴＧＦβ阻害剤 |
| HRP20050247A2 (en) | 2002-09-18 | 2005-10-31 | Pfizer Products Inc. | Pyrazole derivatives as transforming growth factor (tgf) inhibitors |
| MXPA05002332A (es) | 2002-09-18 | 2005-06-08 | Pfizer Prod Inc | Nuevos compuestos de oxazol y tiazol como inhibidores del factor de crecimiento transformador (tgf). |
| PL375973A1 (en) | 2002-09-18 | 2005-12-12 | Pfizer Products Inc. | Novel isothiazole and isoxazole compounds as transforming growth factor (tgf) inhibitors |
| CA2497971A1 (en) | 2002-09-18 | 2004-04-01 | Pfizer Products Inc. | Triazole derivatives as transforming growth factor (tgf) inhibitors |
| JP4547271B2 (ja) | 2002-09-18 | 2010-09-22 | ファイザー・プロダクツ・インク | トランスフォーミング増殖因子（ｔｇｆ）阻害剤としての新規イミダゾール化合物 |
| WO2004048930A2 (en) | 2002-11-22 | 2004-06-10 | Scios, Inc. | METHOD FOR COUNTERACTING A PATHOLOGIC CHANGE IN THE ß-ADRENERGIC PATHWAY |
| US20040138188A1 (en) | 2002-11-22 | 2004-07-15 | Higgins Linda S. | Use of TGF-beta inhibitors to counteract pathologic changes in the level or function of steroid/thyroid receptors |
| CA2513086A1 (en) | 2002-12-19 | 2004-07-08 | Scios Inc. | Treatment of obesity and associated conditions with tgf-.beta. inhibitors |
| US7361669B2 (en) | 2003-01-02 | 2008-04-22 | Millennium Pharmaceuticals, Inc. | Compositions and method for inhibiting TGF-β |
| WO2004065392A1 (en) | 2003-01-24 | 2004-08-05 | Smithkline Beecham Corporation | Condensed pyridines and pyrimidines and their use as alk-5 receptor ligands |
| PA8595001A1 (es) | 2003-03-04 | 2004-09-28 | Pfizer Prod Inc | Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf) |
| CA2517720A1 (en) | 2003-03-11 | 2004-09-23 | Pfizer Products Inc. | Pyrazine compounds as transforming growth factor (tgf) inhibitors |
| ES2305744T3 (es) | 2003-03-12 | 2008-11-01 | Millennium Pharmaceuticals, Inc. | Derivados de quinazolina como inhibidores e tgf-beta. |
| JP2006521398A (ja) | 2003-03-28 | 2006-09-21 | サイオス・インコーポレーテツド | ＴＧＦβの二−環式ピリミジン阻害剤 |
| US20050014753A1 (en) | 2003-04-04 | 2005-01-20 | Irm Llc | Novel compounds and compositions as protein kinase inhibitors |
| US6875781B2 (en) * | 2003-04-04 | 2005-04-05 | Cell Therapeutics, Inc. | Pyridines and uses thereof |
| WO2004112710A2 (en) | 2003-06-17 | 2004-12-29 | Millennium Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS FOR INHIBITING TGF-ß |
| CA2531401A1 (en) | 2003-07-10 | 2005-01-27 | Neurogen Corporation | Substituted heterocyclic diarylamine analogues |
| TW200510373A (en) | 2003-07-14 | 2005-03-16 | Neurogen Corp | Substituted quinolin-4-ylamine analogues |
| US20050036994A1 (en) | 2003-07-16 | 2005-02-17 | Koichiro Mihara | Compounds and methods for downregulating the effects of TGF-beta |
| BRPI0413255A (pt) | 2003-08-01 | 2006-10-03 | Wyeth Corp | uso de uma combinação de um inibidor de quinase do receptor do fator de crescimento epidérmico e agentes citotóxicos para tratamento e inibição do cáncer |
| AU2004278382B2 (en) * | 2003-09-30 | 2008-09-18 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
| US7232824B2 (en) | 2003-09-30 | 2007-06-19 | Scios, Inc. | Quinazoline derivatives as medicaments |
| EP1677734B1 (en) | 2003-10-15 | 2016-04-20 | National Jewish Health | Cystatin c as an antagonist of tgf-b and methods related thereto |
| AR046324A1 (es) | 2003-11-10 | 2005-11-30 | Merck Sharp & Dohme | Heterociclos nitrogenados de seis miembros aminosustituidos que contienen sustituyentes de quinolina o isoquinolina |
| EP1685124A1 (en) | 2003-11-10 | 2006-08-02 | MERCK SHARP & DOHME LTD. | Substituted nitrogen-containing six-membered amino-heterocycles as vanilloid-1 receptor antagonists for treating pain |
| WO2005051915A1 (en) | 2003-11-21 | 2005-06-09 | Merck & Co., Inc. | Pyridin-4-ylamine compounds useful in the treatment of neuropathic pain |
| CN1921864A (zh) * | 2003-12-24 | 2007-02-28 | 西奥斯公司 | 使用TGF－β抑制剂治疗神经胶质瘤 |
| WO2005069935A2 (en) | 2004-01-20 | 2005-08-04 | University Of Medicine And Dentistry Of New Jersey | METHODS FOR MEASURING TRANSFORMING GROWTH FACTOR BETA (TGF-β) RECEPTOR SIGNALING ACTIVITY AND USES THEREOF |
| US7368445B2 (en) | 2004-03-01 | 2008-05-06 | Eli Lilly And Company | Fused pyrazole derivatives as TGF-β signal transduction inhibitors for the treatment of fibrosis and neoplasms |
| WO2006037117A1 (en) * | 2004-09-27 | 2006-04-06 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| WO2006035061A1 (en) | 2004-09-30 | 2006-04-06 | Tibotec Pharmaceuticals Ltd. | Hcv inhibiting bi-cyclic pyrimidines |
| WO2006052568A2 (en) | 2004-11-10 | 2006-05-18 | Eli Lilly And Company | Tgf-beta inhibitors |
| AU2005316668B2 (en) | 2004-12-13 | 2012-09-06 | Millennium Pharmaceuticals, Inc. | Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as RAF kinase inhibitors |
| WO2006102102A2 (en) | 2005-03-17 | 2006-09-28 | Marshfield Clinic | Tgf-beta modulators and methods for using the same |
| US20070066632A1 (en) | 2005-03-25 | 2007-03-22 | Scios, Inc. | Fused bicyclic inhibitors of TGFbeta |
| US20060281763A1 (en) | 2005-03-25 | 2006-12-14 | Axon Jonathan R | Carboxamide inhibitors of TGFbeta |
| BRPI0609650A2 (pt) | 2005-03-25 | 2010-04-20 | Tibotec Pharm Ltd | inibidores heterobicìlicos de hvc |
| MX2007013595A (es) | 2005-05-04 | 2008-01-24 | Renovis Inc | Compuestos heterociclicos fusionados y composiciones y usos de estos. |
| AR054122A1 (es) | 2005-05-12 | 2007-06-06 | Tibotec Pharm Ltd | Pirido[2,3-d]pirimidas utiles como inhibidores de hcv, y metodos para la preparacion de las mismas |
| JP2009539836A (ja) | 2006-06-05 | 2009-11-19 | ジェネンテック・インコーポレーテッド | ＥＧＦまたはＴＧＦ−αのレベルの上昇が生じている癌患者の生存の延長 |
| US20080280891A1 (en) | 2006-06-27 | 2008-11-13 | Locus Pharmaceuticals, Inc. | Anti-cancer agents and uses thereof |
| CA2665438C (en) | 2006-10-04 | 2014-12-02 | Tibotec Pharmaceuticals Ltd. | Carboxamide 4-[(4-pyridyl)amino]pyrimidines useful as hcv inhibitors |
| WO2008057402A2 (en) | 2006-11-02 | 2008-05-15 | Cytovia, Inc. | N-aryl-isoxazolopyrimidin-4-amines and related compounds as activators of caspases and inducers of apoptosis and the use thereof |
| NZ577768A (en) | 2006-12-19 | 2012-01-12 | Vertex Pharma | Aminopyrimidines useful as inhibitors of protein kinases |
| GB0702871D0 (en) | 2007-02-14 | 2007-03-28 | Tcp Innovations Ltd | Improved compositions and combinations 1 |
| AU2008262291A1 (en) | 2007-06-11 | 2008-12-18 | Miikana Therapeutics, Inc. | Substituted pyrazole compounds |
| WO2009012375A2 (en) | 2007-07-19 | 2009-01-22 | Wyeth | Squarate kinase inhibitors |
| WO2009022171A1 (en) * | 2007-08-13 | 2009-02-19 | Astrazeneca Ab | Pyridinyiioxy pyridines as alk5 inhibitors |
| TWI546290B (zh) | 2008-06-27 | 2016-08-21 | 賽基艾維洛米斯研究股份有限公司 | 雜芳基化合物及其用途 |
| CA2744343A1 (en) | 2008-11-19 | 2010-05-27 | Renovis, Inc. | 6, 7 -dihydro- 5h- pyrrolo [3, 4-d] pyrimidin-4-yl] -quinolin-3 -ylamine compounds useful as faah modulators and uses thereof |
| EP2241565A1 (en) | 2009-01-15 | 2010-10-20 | Universität Leipzig | Aurora kinase inhibitors compounds |
| WO2010102267A2 (en) | 2009-03-06 | 2010-09-10 | Ipierian, Inc. | Tgf-beta pathway inhibitors for enhancement of cellular reprogramming of human cells |
| KR101705158B1 (ko) | 2009-05-05 | 2017-02-09 | 다나-파버 캔서 인스티튜트 인크. | Ｅｇｆｒ 억제제 및 질환 치료방법 |
| JP2012530731A (ja) | 2009-06-22 | 2012-12-06 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | ＴＧＦ−β受容体キナーゼモジュレーターとしてのアルコキシ−チエノピリミジン |
| UA108363C2 (uk) * | 2009-10-08 | 2015-04-27 | Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування | |
| CN102596200A (zh) | 2009-11-07 | 2012-07-18 | 默克专利有限公司 | 作为TGF-β受体激酶抑制剂的杂芳基氨基喹啉类 |
| AR079814A1 (es) | 2009-12-31 | 2012-02-22 | Otsuka Pharma Co Ltd | Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos |
| ES2528441T3 (es) | 2010-02-22 | 2015-02-10 | Merck Patent Gmbh | Hetarilaminonaftiridinas |
| US9073918B2 (en) | 2010-05-20 | 2015-07-07 | Takeda Pharmaceutical Company Limited | Pyrazolo[4,3-b]pyridine-7-amine inhibitors of ALK5 |
| AU2011272862A1 (en) | 2010-06-30 | 2013-01-10 | Amgen Inc. | Heterocyclic compounds and their use as inhibitors of PI3K activity |
| WO2012002577A1 (ja) * | 2010-06-30 | 2012-01-05 | 富士フイルム株式会社 | 新規なニコチンアミド誘導体またはその塩 |
| EP2441755A1 (en) | 2010-09-30 | 2012-04-18 | Almirall, S.A. | Pyridine- and isoquinoline-derivatives as Syk and JAK kinase inhibitors |
| EP2635556B1 (en) * | 2010-11-01 | 2017-06-21 | Portola Pharmaceuticals, Inc. | Benzamides and nicotinamides as syk modulators |
| MX2013010163A (es) | 2011-03-09 | 2013-10-30 | Merck Patent Gmbh | Derivados de pirido[2,3-b] pirazina y sus usos terapeuticos. |
| WO2012142329A1 (en) * | 2011-04-12 | 2012-10-18 | Myrexis, Inc. | Compositions and therapeutic uses of ikk-related kinase epsilon and tankbinding kinase 1 inhibitors |
| EP2714081A4 (en) * | 2011-05-27 | 2015-09-09 | Cytocure Llc | METHODS, COMPOSITIONS AND KIT FOR CREAM TREATMENT |
| WO2012177624A2 (en) * | 2011-06-21 | 2012-12-27 | The Johns Hopkins University | Focused radiation for augmenting immune-based therapies against neoplasms |
| WO2013041042A1 (en) * | 2011-09-22 | 2013-03-28 | Merck Sharp & Dohme Corp. | Pyrazole carboxamides as janus kinase inhibitors |
| WO2013078286A1 (en) | 2011-11-22 | 2013-05-30 | Cornell University | Methods for stimulating hematopoietic recovery by inhibiting tgf beta signaling |
| WO2013158422A1 (en) | 2012-04-17 | 2013-10-24 | E. I. Du Pont De Nemours And Company | Heterocyclic compounds for controlling invertebrate pests |
| WO2013175415A1 (en) * | 2012-05-23 | 2013-11-28 | Piramal Enterprises Limited | Substituted pyrimidine compounds and uses thereof |
| EP2863914B1 (en) * | 2012-06-20 | 2018-10-03 | Merck Sharp & Dohme Corp. | Pyrazolyl derivatives as syk inhibitors |
| BR112015013247B1 (pt) * | 2012-12-11 | 2022-07-12 | Koninklijke Philips N.V. | Aparelho auxiliar para assistir na realização da braquiterapia, sistema de braquiterapia para aplicar braquiterapia a um objeto vivo, e método auxiliar para assistir na realização da braquiterapia |
| EP2976336A1 (en) | 2013-03-21 | 2016-01-27 | Bayer Pharma Aktiengesellschaft | 3-heteroaryl substituted indazoles |
| WO2014181287A1 (en) | 2013-05-09 | 2014-11-13 | Piramal Enterprises Limited | Heterocyclyl compounds and uses thereof |
| HRP20201384T1 (hr) | 2014-01-01 | 2020-11-27 | Medivation Technologies Llc | Spojevi i postupci njihove upotrebe |
| TW201609693A (zh) | 2014-01-03 | 2016-03-16 | 必治妥美雅史谷比公司 | 雜芳基取代之菸鹼醯胺化合物 |
| JO3336B1 (ar) | 2014-10-07 | 2019-03-13 | Lilly Co Eli | مركبات أمينو بيريديلوكسي بيرازول |
| TW201630907A (zh) | 2014-12-22 | 2016-09-01 | 必治妥美雅史谷比公司 | ＴＧＦβＲ拮抗劑 |
| US10030000B2 (en) | 2016-09-21 | 2018-07-24 | Celanese International Corporation | Acesulfame potassium compositions and processes for producing same |
-
2014
- 2014-12-31 HR HRP20201384TT patent/HRP20201384T1/hr unknown
- 2014-12-31 LT LTEP14824755.4T patent/LT3089971T/lt unknown
- 2014-12-31 HU HUE14824755A patent/HUE050761T2/hu unknown
- 2014-12-31 SI SI201431651T patent/SI3089971T1/sl unknown
- 2014-12-31 CN CN201480075343.2A patent/CN106132950B/zh not_active Expired - Fee Related
- 2014-12-31 CN CN201810955135.1A patent/CN109045032A/zh active Pending
- 2014-12-31 DK DK14824755.4T patent/DK3089971T3/da active
- 2014-12-31 CA CA2935392A patent/CA2935392C/en active Active
- 2014-12-31 PT PT148247554T patent/PT3089971T/pt unknown
- 2014-12-31 RS RS20201011A patent/RS60718B1/sr unknown
- 2014-12-31 AU AU2014373773A patent/AU2014373773C1/en not_active Ceased
- 2014-12-31 JP JP2016544111A patent/JP6474166B2/ja not_active Expired - Fee Related
- 2014-12-31 EP EP14824755.4A patent/EP3089971B1/en active Active
- 2014-12-31 ES ES14824755T patent/ES2813875T3/es active Active
- 2014-12-31 US US15/109,013 patent/US10030004B2/en active Active
- 2014-12-31 WO PCT/US2014/072922 patent/WO2015103355A1/en not_active Ceased
- 2014-12-31 PL PL14824755T patent/PL3089971T3/pl unknown
-
2018
- 2018-03-23 US US15/933,532 patent/US10501436B2/en active Active
- 2018-12-20 AU AU2018282363A patent/AU2018282363B2/en not_active Ceased
-
2019
- 2019-01-04 JP JP2019000208A patent/JP2019048899A/ja active Pending
- 2019-10-22 US US16/659,775 patent/US11053216B2/en active Active
-
2020
- 2020-08-28 CY CY20201100809T patent/CY1123290T1/el unknown
-
2021
- 2021-05-22 US US17/327,705 patent/US11702401B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017501200A5 (https=) | ||
| ES2935633T3 (es) | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos | |
| AU2018346712B2 (en) | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD | |
| JP2022058398A (ja) | Ｂｒａｆ－ｖ６００関連疾患の治療に使用するためのｐｌｘ－８３９４またはｐｌｘ－７９０４ | |
| KR101780666B1 (ko) | Ｉｌ-23 매개 질환의 치료에서 ｅｐ4 수용체 길항제의 용도 | |
| ES2910071T3 (es) | Compuestos de aminopirazina diol como inhibidores de PI3K-Y | |
| BR112020025073A2 (pt) | moduladores de montagem de capsídeo da hepatite b | |
| KR20230028484A (ko) | 암의 치료를 위한 병용 요법 | |
| HRP20201216T1 (hr) | PRIPRAVCI I POSTUPCI ZA LIJEČENJE POREMEĆAJA CNS-a | |
| CN116783180A (zh) | 用于降解ikzf2或ikzf4的三环配体 | |
| RU2018106453A (ru) | Соединения | |
| CN114026072A (zh) | 治疗特发性肺纤维化的方法 | |
| JP2018536681A (ja) | インフルエンザウイルス複製の阻害剤、その適用方法および使用 | |
| US20210361629A1 (en) | Thiazolidinedione analogs for the treatment of nafld and metabolic diseases | |
| CN116437913A (zh) | 用于治疗补体介导的病症的药物化合物 | |
| US20170174688A1 (en) | Substituted Indoles | |
| JP2015172098A5 (https=) | ||
| WO2007002051A1 (en) | Carboline derivatives and their use as inhibitors of flaviviridae infections | |
| CN102482272A (zh) | 情绪障碍治疗剂 | |
| WO2015134171A1 (en) | Heteroarylamide inhibitors of tbk1 | |
| JPWO2013002365A1 (ja) | 止痒剤 | |
| JP2015521639A5 (https=) | ||
| US20170007615A1 (en) | Antibacterial Compounds | |
| ES2363056T3 (es) | Utilización de 4-ciclopropilmetoxi-n-(3,5-dicloro-1-óxido-piridin-4-il)-5-(metoxi)piridin-2-carboxamida para el tratamiento de los traumatismos de la médula espinal. | |
| US9549921B2 (en) | Heterocyclic compounds and methods of use thereof for the treatment of hepatitis C |